320 related articles for article (PubMed ID: 15095485)
1. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
3. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
4. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
Moliterno AR; Hankins WD; Spivak JL
N Engl J Med; 1998 Feb; 338(9):572-80. PubMed ID: 9475764
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of insulin-like growth factor-2 (IGF-2) in Philadelphia chromosome negative chronic myeloproliferative disorders.
Bock O; Tessema M; Serinsöz E; von Wasielewski R; Büsche G; Kreipe H
Leuk Res; 2004 Nov; 28(11):1145-51. PubMed ID: 15380337
[TBL] [Abstract][Full Text] [Related]
6. Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders.
Duensing S; Duensing A; Meran JG; Kreft A; Büsche G; Ganser A; Georgii A
Mol Pathol; 1999 Jun; 52(3):146-50. PubMed ID: 10621836
[TBL] [Abstract][Full Text] [Related]
7. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
[TBL] [Abstract][Full Text] [Related]
8. Constitutive expression of the FK506 binding protein 51 (FKBP51) in bone marrow cells and megakaryocytes derived from idiopathic myelofibrosis and non-neoplastic haematopoiesis.
Bock O; Neusch M; Büsche G; Mengel M; Kreipe H
Eur J Haematol; 2004 Apr; 72(4):239-44. PubMed ID: 15089760
[TBL] [Abstract][Full Text] [Related]
9. Transcription factor Fli-1 expression by bone marrow cells in chronic myeloproliferative disorders is independent of an underlying JAK2 (V617F) mutation.
Bock O; Hussein K; Neusch M; Schlué J; Wiese B; Kreipe H
Eur J Haematol; 2006 Dec; 77(6):463-70. PubMed ID: 16930139
[TBL] [Abstract][Full Text] [Related]
10. [Expression of thrombopoietin related genes in patients with idiopathic thrombocytopenic purpura].
Zhang X; Yang Y; Shi H
Zhonghua Xue Ye Xue Za Zhi; 1998 Nov; 19(11):587-9. PubMed ID: 11263344
[TBL] [Abstract][Full Text] [Related]
11. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates.
Yoon SY; Li CY; Tefferi A
Eur J Haematol; 2000 Sep; 65(3):170-4. PubMed ID: 11007052
[TBL] [Abstract][Full Text] [Related]
12. Early down-regulation of Bcl-xL expression during megakaryocytic differentiation of thrombopoietin-induced CD34+ bone marrow cells in essential thrombocythemia.
Zhang L; Zhao H; Sun A; Lu S; Liu B; Tang F; Feng Y; Zhao L; Yang R; Han ZC
Haematologica; 2004 Oct; 89(10):1199-206. PubMed ID: 15477204
[TBL] [Abstract][Full Text] [Related]
13. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia.
Li J; Xia Y; Kuter DJ
Br J Haematol; 2000 Dec; 111(3):943-53. PubMed ID: 11122159
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of beta-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia.
Serinsöz E; Neusch M; Büsche G; Wasielewski R; Kreipe H; Bock O
Br J Haematol; 2004 Aug; 126(3):313-9. PubMed ID: 15257703
[TBL] [Abstract][Full Text] [Related]
15. Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation.
Alexander WS; Roberts AW; Maurer AB; Nicola NA; Dunn AR; Metcalf D
Stem Cells; 1996; 14 Suppl 1():124-32. PubMed ID: 11012212
[TBL] [Abstract][Full Text] [Related]
16. A novel thrombopoietin signaling defect in polycythemia vera platelets.
Moliterno AR; Siebel KE; Sun AY; Hankins WD; Spivak JL
Stem Cells; 1998; 16 Suppl 2():185-92. PubMed ID: 11012190
[TBL] [Abstract][Full Text] [Related]
17. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
Tefferi A
Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
[TBL] [Abstract][Full Text] [Related]
18. Etiology of the myeloproliferative disorders: the role of thrombopoietin.
Kaushansky K
Semin Hematol; 2003 Jan; 40(1 Suppl 1):6-9. PubMed ID: 12682875
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloproliferative diseases on a pathologist's desk--a dilemma of distinct entities versus a clinico-pathologic continuum. A descriptive study based on a material from the Polish population.
Rudzki Z; Papla B; Stachura J
Pol J Pathol; 2004; 55(1):13-23. PubMed ID: 15195702
[TBL] [Abstract][Full Text] [Related]
20. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]